Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.68 |
| ▸ | LMNA | P02545 | 3/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | CASR | P41180 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.47 |
| ▸ | SELP | P16109 | 1/20 | 0.46 |
| ▸ | SELE | P16581 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | ALB | P02768 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3716517 | 0.84 | KMT2A (0.65) | KDM4ELMNAALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL6695143 | 0.83 | KDM4E (0.48) | KDM4ELMNAALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL4294304 | 0.83 | ALDH1A1 (0.68) | KDM4ELMNAALDH1A1SMN1; SMN2CASR | |
| SCHEMBL3633756 | 0.82 | SMN1; SMN2 (0.66) | KDM4ELMNAALDH1A1SMN1; SMN2CASR | |
| SCHEMBL4290828 | 0.81 | KDM4E (0.59) | KDM4ELMNAALDH1A1SMN1; SMN2CASR | |
| SCHEMBL4289827 | 0.81 | KDM4E (0.64) | KDM4ELMNAALDH1A1SMN1; SMN2CASR | |
| SCHEMBL30810149 | 0.80 | ALDH1A1 (0.63) | KDM4ELMNAALDH1A1SMN1; SMN2CASR | |
| SCHEMBL14270910 | 0.79 | POLB (0.44) | KDM4ELMNAALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL30810156 | 0.76 | DHODH (0.63) | KDM4ELMNAALDH1A1SMN1; SMN2CASR | |
| SCHEMBL6688900 | 0.76 | TDP1 (0.56) | ALDH1A1SMN1; SMN2TDP1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8022172-B2 | Clostridial toxin substrate comprising fluorphore, lanthanide donor complex and botulin toxin recognition sequence for use in detecting clostridial protease activity | ALLERGAN, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-7846722-B2 | Luminescence resonance energy transfer (LRET) assays for clostridial toxin activity | ALLERGAN, INC. (US) | 2010-12-07 | — | — | US | disclosed |
| US-20080220456-A1 | LUMINESCENCE RESONANCE ENERGY TRANSFER (LRET) ASSAYS FOR CLOSTRIDIAL TOXIN ACTIVITY | ALLERGAN, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080064054-A1 | FLUORESCENCE RESONANCE ENERGY TRANSFER (FRET) ASSAYS FOR CLOSTRIDIAL TOXIN ACTIVITY | ALLERGAN, INC. | 2008-03-13 | — | — | US | disclosed |
| US-20070243565-A1 | LUMINESCENCE RESONANCE ENERGY TRANSFER (LRET) ASSAYS FOR CLOSTRIDIAL TOXIN ACTIVITY | ALLERGAN, INC. | 2007-10-18 | — | — | US | disclosed |
| EP-1792185-A2 | LANTHANIDE-BASED SUBSTRATES AND METHODS FOR DETERMINING CLOSTRIDIAL TOXIN ACTIVITY | Allergan, Inc. (US) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006033843-A2 | LANTHANIDE-BASED SUBSTRATES AND METHODS FOR DETERMINING CLOSTRIDIAL TOXIN ACTIVITY | ALLERGAN, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| US-20060063221-A1 | Lanthanide-based substrates and methods for determining clostridial toxin activity | ALLERGAN, INC. | 2006-03-23 | — | — | US | disclosed |
| EP-1594538-A2 | COMPOSITION TO BE ADMINISTERED TO A LIVING BEING AND METHOD FOR MARKING AGENTS | responsif GmbH (DE) | 2005-11-16 | — | — | EP | disclosed |
| WO-2004073738-A2 | COMPOSITION TO BE ADMINISTERED TO A LIVING BEING AND METHOD FOR MARKING AGENTS | RESPONSIF GMBH (DE) | 2004-09-02 | — | — | WO | disclosed |
| US-6528275-B1 | Screening for cleavage using combinatorial fluorescence resonance energy transfer (FRET) compounds of given formula; can use to accelerate drug discovery process | PEPTIDE THERAPEUTICS LIMITED (GB) | 2003-03-04 | — | — | US | disclosed |
| EP-0458901-B1 | INHIBITING TRANSFORMATION OF CELLS HAVING ELEVATED PURINE METABOLIC ENZYME ACTIVITY | MASSACHUSETTS INST TECHNOLOGY (US) | 1997-12-17 | — | — | EP | disclosed |
| EP-0758681-A2 | Inhibiting transformation of cells having elevated purine metabolic enzyme activity | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1997-02-19 | — | — | EP | disclosed |
| US-5324731-A | Method of inhibiting transformation of cells in which purine metabolic enzyme activity is elevated | AMIRA, INC. (US) | 1994-06-28 | — | — | US | disclosed |
| EP-0557383-A1 | METHOD OF INHIBITING TRANSFORMATION, GROWTH AND METASTASIS OF CELLS IN WHICH PURINE METABOLIC ENZYME ACTIVITY IS ELEVATED | AMIRA, INC. (US) | 1993-09-01 | — | — | EP | disclosed |
| WO-1992008456-A2 | METHOD OF INHIBITING TRANSFORMATION, GROWTH AND METASTASIS OF CELLS IN WHICH PURINE METABOLIC ENZYME ACTIVITY IS ELEVATED | AMIRA, INC. (US) | 1992-05-29 | — | — | WO | disclosed |
| EP-0458901-A1 | INHIBITING TRANSFORMATION OF CELLS HAVING ELEVATED PURINE METABOLIC ENZYME ACTIVITY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1991-12-04 | — | — | EP | disclosed |
| WO-1990009192-A1 | INHIBITING TRANSFORMATION OF CELLS HAVING ELEVATED PURINE METABOLIC ENZYME ACTIVITY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1990-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080220456-A1 | LUMINESCENCE RESONANCE ENERGY TRANSFER (LRET) ASSAYS FOR CLOSTRIDIAL TOXIN ACTIVITY | LCT, LRBA, LTA | KDM4E 3807/4885LMNA 613/4885ALDH1A1 4793/4885 |
| US-20080064054-A1 | FLUORESCENCE RESONANCE ENERGY TRANSFER (FRET) ASSAYS FOR CLOSTRIDIAL TOXIN ACTIVITY | ANTXR2, TRAM1, TOMM34 | KDM4E 4739/4885LMNA 1445/4885ALDH1A1 4811/4885 |
| US-20070243565-A1 | LUMINESCENCE RESONANCE ENERGY TRANSFER (LRET) ASSAYS FOR CLOSTRIDIAL TOXIN ACTIVITY | LCT, LRBA, LTA | KDM4E 3807/4885LMNA 613/4885ALDH1A1 4793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.